April 1, 2026 · Form 4 insider transaction
Dambkowski Carl sold 100 shares of Apogee Therapeutics, Inc. at $85.89 per share, a transaction worth $8.6K. The trade was recorded as open-market sale under a pre-scheduled Rule 10b5-1 plan and disclosed on an SEC Form 4, filed 2 days after the transaction.
This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 22, 2025.